布地奈德联合复方异丙托溴铵治疗小儿肺炎的临床效果

Clinical Effect of Budesonide Combined with Compound Ipratropium Bromide in the Treatment of Children with Pneumonia

目的分析布地奈德联合复方异丙托溴铵治疗小儿肺炎的临床应用效果。方法该研究便利选择2017年1月—2020年12月该院接受治疗的小儿肺炎患儿110例进行研究,入院编码,把1~55号患儿纳入对照组中,不接受雾化吸入治疗,给予常规药物治疗,把56~110号患儿纳入观察组中,采用布地奈德联合复方异丙托溴铵治疗,观察两组患儿咳嗽症状、症状改善状况与住院时间,同时观察两组患儿用药的不良反应,评估临床治疗效果。结果观察组患儿治疗前的咳嗽症状评分(2.58±0.34)分与对照组数据(2.60±0.33)分间的差异无统计学意义(t=0.313,P>0.05),而治疗后3、5 d的咳嗽症状评分分别是(1.94±0.17)分、(1.34±0.11)分,较对照组各项数据(2.15±0.25)分、(1.76±0.32)分更优,差异有统计学意义(t=5.151、9.205,P<0.05);观察组患儿喘憋消除时间、湿罗音消除时间、咳嗽消除时间分别是(3.66±0.83)、(3.96±0.66)、(7.60±0.54)d,住院时间是(8.96±1.32)d,与对照组各项数据(4.40±0.72)、(5.18±0.63)、(8.80±1.19)、(11.17±1.35)d相比,明显更低,差异有统计学意义(t=4.995、9.916、6.810、8.861,P<0.05);观察组患儿用药不良反应发生5.45%(3/55)明显较对照组18.18%(10/55)更低,且临床治疗总有效率96.36%(53/55)明显较对照组85.45%(47/55)更高,差异有统计学意义(χ^(2)=4.274、3.960,P<0.05)。结论针对小儿肺炎疾病,临床给予布地奈德联合复方异丙托溴铵治疗的有效性较高,可以有效改善患儿咳嗽症状,缩短喘憋、咳嗽、湿啰音症状的消除时间,不良反应少,安全性高,在临床中应当大力推广和应用。

Objective To analyze the clinical application effect of budesonide combined with compound ipratropium bromide in the treatment of children with pneumonia.Methods The study conveniently selected 110 children with pediatric pneumonia who were treated in the hospital from January 2017 to December 2020 for the study,with the admission code,and included children with numbers 1 to 55 in the control group.They did not receive aerosol inhalation treatment and were given routine Drug treatment,included children with 56-110 in the observation group,treated with budesonide combined with compound ipratropium bromide,observed the cough symptoms,symptom improvement and hospitalization time of the two groups of children,and observed the medication of the two groups at the same time adverse reactions,evaluate the clinical treatment effect.Results There was no significant difference between the observation group's cough symptom score(2.58±0.34)points before treatment and the control group's(2.60±0.33)points(t=0.313,P>0.05),and 3 d,5 after treatment The cough symptom scores of d were(1.94±0.17)points and(1.34±0.11)points,which were better than those of the control group(2.15±0.25)points and(1.76±0.32)points.The difference was statistically significant(t=5.151,9.205,P<0.05);the time to eliminate wheezing,the time to eliminate wet rales,and the time to eliminate cough in the observation group were(3.66±0.83)d,(3.96±0.66)d,and(7.60±0.54)d,respectively,The length of hospital stay was(8.96±1.32)d,which was significantly lower than the data of the control group(4.40±0.72)d,(5.18±0.63)d,(8.80±1.19)d,(11.17±1.35)d,the difference was statistically significant(t=4.995,9.916,6.810,8.861,P<0.05);adverse drug reactions occurred in 5.45%(3/55)of children in the observation group were significantly lower than 18.18%(10/55)in the control group,and the total effective rate of clinical treatment was 96.36%(53/55)was significantly higher than that of the control group 85.45%(47/55),the difference was statistically significant(χ^(2)=4.274,3.960,P<0.05).Conclusion For children with pneumonia,the clinical treatment of budesonide combined with compound ipratropium bromide is effective,which can effectively improve the symptoms of cough in children,shorten the elimination time of wheezing,cough,and wet rales,with less adverse reaction,high safety,should be vigorously promoted and applied in clinical practice.